泌尿器癌骨転移症例に対するデノスマブの短期治療成績

Short-term effects of denosmab for patients with bone metastasis from urological malignancies

　デノスマブは，固形癌骨転移症例の骨関連事象（skeletal-related events：SRE）のリスクを低下させる。本研究では2012年4～6月にデノスマブが投与された骨転移を有する泌尿器癌症例15例を対象とし，デノスマブの初期使用症例について安全性を検証した。また，ゾレドロン酸投与歴のある前立腺癌6症例において血清骨代謝マーカーを測定し，短期的効果を検討した。有害事象は無症候性の低カルシウム血症が4例，肝機能障害が1例に認められた。また，ゾレドロン酸投与時に骨代謝マーカー高値を示した症例で，デノスマブ投与後の改善を認めた。デノスマブは低カルシウム血症が高頻度に認められるものの安全に投与可能であり，また強い骨吸収抑制効果を持つことが示唆された。

To evaluate the safety of denosumab, which can reduce the risk of skeletal-related events（SRE）we investigated the clinical course of 15 patients who had urological cancers with bone metastasis and were treated with denosumab between April 2012 and June 2012. Markers of bone metabolism were measured in six prostate cancer patients who had been treated with zoledronic acid before administration of denosumab to evaluate the short-term efficacy. Adverse events associated with denosumab consisted of asymptomatic hypocalcaemia in 4 patients and elevation of transaminase in 1 patient. In a patient whose bone resorption markers had been elevated during the use of zoledronic acid, the level of markers was improved after administration of denosumab. Although frequently accompanied by hypocalcemia, denosumab can be used safely and may have a superior inhibitory effect against bone resorption.